T-cell receptor recognizing Human papillomavirus L1-derived peptides in MHC class II (HPV L1-specific TCR)

The T-cell receptor (TCR) on CD4+ T helper cells that recognizes Human Papillomavirus (HPV) L1-derived peptides presented by MHC class II molecules is a central mediator of the adaptive immune response against HPV (Source: PubMed, PMID: 15105288). HPV L1 is the major capsid protein and the primary antigen used in prophylactic vaccines such as Gardasil 9 and Cervarix (Source: FDA). Upon vaccination or infection, antigen-presenting cells (APCs) internalize the L1 protein, process it into peptides, and display them on MHC class II molecules for recognition by specific TCRs on CD4+ T cells (Source: Janeway's Immunobiology, 9th edition). This recognition event triggers T-cell activation and the production of cytokines like IL-4 and IL-2, which are vital for B-cell help and the generation of neutralizing antibodies that block viral entry (Source: PubMed, PMID: 21835963). While L1-specific responses are primarily prophylactic, understanding these TCRs is crucial for monitoring vaccine efficacy and developing therapeutic strategies for persistent infections (Source: PubMed, PMID: 25607361).

Other names

HPV L1-specific T-cell receptorCD4+ HPV L1 TCRHuman papillomavirus L1-specific TCRMHC class II-restricted HPV L1 TCR

Activation of CD4+ T helper cells through the binding of the T-cell receptor to HPV L1 peptides presented by MHC class II molecules, facilitating B-cell activation and antibody production (Source: PubMed, PMID: 21835963).